GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most co...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/4/947 |
| _version_ | 1797571920103735296 |
|---|---|
| author | José Luis Górriz María José Soler Juan F. Navarro-González Clara García-Carro María Jesús Puchades Luis D’Marco Alberto Martínez Castelao Beatriz Fernández-Fernández Alberto Ortiz Carmen Górriz-Zambrano Jorge Navarro-Pérez Juan José Gorgojo-Martinez |
| author_facet | José Luis Górriz María José Soler Juan F. Navarro-González Clara García-Carro María Jesús Puchades Luis D’Marco Alberto Martínez Castelao Beatriz Fernández-Fernández Alberto Ortiz Carmen Górriz-Zambrano Jorge Navarro-Pérez Juan José Gorgojo-Martinez |
| author_sort | José Luis Górriz |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD. |
| first_indexed | 2024-03-10T20:48:26Z |
| format | Article |
| id | doaj.art-00209136b6bc45dc94061334669ce90f |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T20:48:26Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-00209136b6bc45dc94061334669ce90f2023-11-19T20:08:05ZengMDPI AGJournal of Clinical Medicine2077-03832020-03-019494710.3390/jcm9040947GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to NephrologistsJosé Luis Górriz0María José Soler1Juan F. Navarro-González2Clara García-Carro3María Jesús Puchades4Luis D’Marco5Alberto Martínez Castelao6Beatriz Fernández-Fernández7Alberto Ortiz8Carmen Górriz-Zambrano9Jorge Navarro-Pérez10Juan José Gorgojo-Martinez11Nephrology Department, Hospital Clínico Universitario, INCLIVA, Universidad de Valencia, 46010 Valencia, SpainNephrology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, SpainUnidad de Investigación y Servicio de Nefrología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Universidad de La Laguna, 38200 Tenerife, SpainNephrology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, SpainNephrology Department, Hospital Clínico Universitario, INCLIVA, Universidad de Valencia, 46010 Valencia, SpainNephrology Department, Hospital Clínico Universitario, INCLIVA, Universidad de Valencia, 46010 Valencia, SpainIIS-Fundación Jimenez Diaz UAM and School of Medicine, Universidad Autonoma de Madrid, 28040 Madrid, SpainNephrology Department, Bellvitge University Hospital, Hospitalet, 08907 Barcelona, SpainIIS-Fundación Jimenez Diaz UAM and School of Medicine, Universidad Autonoma de Madrid, 28040 Madrid, SpainCAP Sant Pere, ABS Reus 1, 43202 Tarragona, SpainHospital Clínico Universitario Valencia, INCLIVA, Universidad de Valencia, 46010 Valencia, SpainUnidad de Endocrinología y Nutrición, Fundación Hospital Alcorcón, 28922 Madrid, SpainType 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a new class of anti-hyperglycemic drugs shown to improve cardiovascular and renal events in DKD. In this regard, GLP-1RA offer the potential for adequate glycemic control in multiple stages of DKD without an increased risk of hypoglycemia, preventing the onset of macroalbuminuria and slowing the decline of glomerular filtration rate (GFR) in diabetic patients, also bringing additional benefit in weight reduction, cardiovascular and other kidney outcomes. Results from ongoing trials are pending to assess the impact of GLP-1RA treatments on primary kidney endpoints in DKD.https://www.mdpi.com/2077-0383/9/4/947chronic kidney diseasediabetic kidney diseaseGLP-1 |
| spellingShingle | José Luis Górriz María José Soler Juan F. Navarro-González Clara García-Carro María Jesús Puchades Luis D’Marco Alberto Martínez Castelao Beatriz Fernández-Fernández Alberto Ortiz Carmen Górriz-Zambrano Jorge Navarro-Pérez Juan José Gorgojo-Martinez GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists Journal of Clinical Medicine chronic kidney disease diabetic kidney disease GLP-1 |
| title | GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists |
| title_full | GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists |
| title_fullStr | GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists |
| title_full_unstemmed | GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists |
| title_short | GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists |
| title_sort | glp 1 receptor agonists and diabetic kidney disease a call of attention to nephrologists |
| topic | chronic kidney disease diabetic kidney disease GLP-1 |
| url | https://www.mdpi.com/2077-0383/9/4/947 |
| work_keys_str_mv | AT joseluisgorriz glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT mariajosesoler glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT juanfnavarrogonzalez glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT claragarciacarro glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT mariajesuspuchades glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT luisdmarco glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT albertomartinezcastelao glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT beatrizfernandezfernandez glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT albertoortiz glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT carmengorrizzambrano glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT jorgenavarroperez glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists AT juanjosegorgojomartinez glp1receptoragonistsanddiabetickidneydiseaseacallofattentiontonephrologists |